Stock listing
KRX:0009K0 Aimed Bio Inc. (에임드바이오) 주가
Follow Aimed Bio Inc. into a list and get an email when it puts out news.
Share price · KRX:0009K0
₩15,150 KRW -780 (-4.9%)
Close on Nov 20, 2026
- Day range
- ₩15,080 – ₩16,000 KRWNov 20, 2026
- Volume
- 183,491 sharesNov 20, 2026
- Market cap
- ₩972.0B KRWAt the close on Nov 20, 2026 · price × 64.16M shares outstanding
- Traded on an average day
- ₩2.70B KRWMedian day 109,984 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:0009K0 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩15,150 | -780 | -4.9% | ₩16,000 | ₩16,000 | ₩15,080 | 183,491 | |
| ₩15,930 | -100 | -0.6% | ₩16,180 | ₩17,050 | ₩15,830 | 181,083 | |
| ₩16,030 | -470 | -2.8% | ₩15,990 | ₩16,740 | ₩15,700 | 193,993 | |
| ₩16,500 | -1,810 | -9.9% | ₩18,520 | ₩18,820 | ₩16,310 | 264,364 | |
| ₩18,310 | -900 | -4.7% | ₩19,580 | ₩20,600 | ₩18,310 | 219,353 | |
| ₩19,210 | -550 | -2.8% | ₩19,680 | ₩19,800 | ₩18,950 | 90,967 | |
| ₩19,760 | +1,160 | +6.2% | ₩18,440 | ₩19,850 | ₩18,440 | 146,017 | |
| ₩18,600 | +690 | +3.9% | ₩18,340 | ₩19,400 | ₩17,910 | 136,593 | |
| ₩17,910 | -340 | -1.9% | ₩18,070 | ₩18,760 | ₩17,420 | 122,356 | |
| ₩18,250 | -820 | -4.3% | ₩17,470 | ₩19,150 | ₩17,190 | 165,356 | |
| ₩19,070 | +270 | +1.4% | ₩19,200 | ₩20,050 | ₩18,800 | 154,370 | |
| ₩18,800 | +440 | +2.4% | ₩18,390 | ₩18,800 | ₩17,390 | 191,221 | |
| ₩18,360 | -850 | -4.4% | ₩18,820 | ₩19,340 | ₩18,300 | 115,426 | |
| ₩19,210 | +350 | +1.9% | ₩18,690 | ₩19,470 | ₩18,600 | 89,849 | |
| ₩18,860 | -990 | -5.0% | ₩19,850 | ₩19,850 | ₩18,540 | 151,538 | |
| ₩19,850 | -1,000 | -4.8% | ₩21,650 | ₩21,850 | ₩19,700 | 246,080 | |
| ₩20,850 | +300 | +1.5% | ₩20,600 | ₩21,400 | ₩20,550 | 105,916 | |
| ₩20,550 | -1,250 | -5.7% | ₩22,250 | ₩22,800 | ₩20,450 | 216,320 | |
| ₩21,800 | +900 | +4.3% | ₩22,200 | ₩23,150 | ₩20,900 | 349,753 | |
| ₩20,900 | -450 | -2.1% | ₩21,250 | ₩21,600 | ₩20,400 | 103,403 | |
| ₩21,350 | -650 | -3.0% | ₩21,850 | ₩22,450 | ₩21,150 | 104,630 | |
| ₩22,000 | -550 | -2.4% | ₩23,000 | ₩23,800 | ₩21,850 | 109,554 | |
| ₩22,550 | +350 | +1.6% | ₩21,600 | ₩23,150 | ₩21,300 | 104,092 | |
| ₩22,200 | +1,400 | +6.7% | ₩20,750 | ₩22,400 | ₩20,100 | 118,071 | |
| ₩20,800 | +1,620 | +8.4% | ₩19,350 | ₩21,500 | ₩19,320 | 114,835 | |
| ₩19,180 | -1,570 | -7.6% | ₩19,980 | ₩20,200 | ₩18,570 | 136,117 | |
| ₩20,750 | +50 | +0.2% | ₩20,850 | ₩21,350 | ₩20,400 | 99,021 | |
| ₩20,700 | -1,500 | -6.8% | ₩21,350 | ₩21,800 | ₩20,000 | 156,824 | |
| ₩22,200 | -2,050 | -8.5% | ₩24,200 | ₩24,500 | ₩21,800 | 105,076 | |
| ₩24,250 | -1,650 | -6.4% | ₩25,650 | ₩25,750 | ₩24,050 | 116,369 | |
| ₩25,900 | +100 | +0.4% | ₩26,150 | ₩26,450 | ₩25,550 | 108,074 | |
| ₩25,800 | +1,000 | +4.0% | ₩25,200 | ₩26,450 | ₩25,100 | 157,625 | |
| ₩24,800 | -650 | -2.6% | ₩25,400 | ₩25,900 | ₩24,250 | 106,646 | |
| ₩25,450 | +3,100 | +13.9% | ₩22,100 | ₩25,600 | ₩22,000 | 231,943 | |
| ₩22,350 | +850 | +4.0% | ₩21,500 | ₩22,600 | ₩21,150 | 100,076 | |
| ₩21,500 | -850 | -3.8% | ₩22,100 | ₩22,150 | ₩20,800 | 110,414 | |
| ₩22,350 | +950 | +4.4% | ₩22,200 | ₩22,900 | ₩22,000 | 119,817 | |
| ₩21,400 | +200 | +0.9% | ₩21,150 | ₩21,700 | ₩20,900 | 85,923 | |
| ₩21,200 | -450 | -2.1% | ₩21,850 | ₩22,150 | ₩20,900 | 133,603 | |
| ₩21,650 | -100 | -0.5% | ₩21,550 | ₩21,850 | ₩21,150 | 105,991 | |
| ₩21,750 | -900 | -4.0% | ₩22,650 | ₩22,750 | ₩21,550 | 248,033 | |
| ₩22,650 | +50 | +0.2% | ₩22,950 | ₩23,200 | ₩22,350 | 71,019 | |
| ₩22,600 | 0 | 0.0% | ₩22,350 | ₩22,700 | ₩22,000 | 54,287 | |
| ₩22,600 | +450 | +2.0% | ₩22,350 | ₩23,000 | ₩22,200 | 68,413 | |
| ₩22,150 | -500 | -2.2% | ₩22,050 | ₩22,400 | ₩21,650 | 80,334 | |
| ₩22,650 | -1,050 | -4.4% | ₩22,700 | ₩23,100 | ₩22,450 | 74,187 | |
| ₩23,700 | +100 | +0.4% | ₩23,500 | ₩23,700 | ₩22,600 | 85,447 | |
| ₩23,600 | -100 | -0.4% | ₩23,300 | ₩24,250 | ₩23,200 | 54,439 | |
| ₩23,700 | -550 | -2.3% | ₩24,050 | ₩24,300 | ₩23,600 | 69,355 | |
| ₩24,250 | +800 | +3.4% | ₩23,650 | ₩24,300 | ₩23,250 | 61,792 | |
| ₩23,450 | +1,050 | +4.7% | ₩22,600 | ₩23,850 | ₩22,550 | 74,543 | |
| ₩22,400 | -800 | -3.4% | ₩23,850 | ₩24,000 | ₩22,200 | 91,031 | |
| ₩23,200 | -550 | -2.3% | ₩23,000 | ₩24,400 | ₩22,750 | 114,869 | |
| ₩23,750 | -750 | -3.1% | ₩24,300 | ₩24,800 | ₩23,500 | 105,857 | |
| ₩24,500 | -600 | -2.4% | ₩24,200 | ₩25,050 | ₩23,600 | 89,750 | |
| ₩25,100 | -600 | -2.3% | ₩25,500 | ₩26,250 | ₩24,750 | 81,222 | |
| ₩25,700 | +300 | +1.2% | ₩25,250 | ₩25,750 | ₩25,100 | 62,254 | |
| ₩25,400 | -600 | -2.3% | ₩25,950 | ₩26,500 | ₩25,350 | 72,646 | |
| ₩26,000 | +50 | +0.2% | ₩25,500 | ₩26,050 | ₩24,150 | 102,028 | |
| ₩25,950 | +1,450 | +5.9% | ₩24,650 | ₩26,450 | ₩24,650 | 130,352 | |
| ₩24,500 | -1,950 | -7.4% | ₩25,450 | ₩25,650 | ₩24,300 | 110,550 | |
| ₩26,450 | +350 | +1.3% | ₩27,550 | ₩27,900 | ₩25,850 | 126,370 |
- Ticker
- KRX:0009K0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Feb 6, 2026
Aimed Bio Q4 Operating Profit 25.3 Billion Won, Up 200% From Year Earlier
Latest news
Aimed Bio Q4 Operating Profit 25.3 Billion Won, Up 200% From Year Earlier
Feb 5, 2026
Closed ₩52,000 (-4.4%) on Feb 6, 2026
Aimed Bio To Receive Licensing Fees From Sk Plasma For Amb303 Pipeline
Dec 26, 2025
Closed ₩64,900 (+4.3%) on Dec 26, 2025
Aimed Bio Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Feb 6, 2026 · oldest 2025
Valuation
P/E 25.2× against a median of 9.8×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩879.3B KRW
- P/E
- 25.2×
- EV/sales
- 13.2×
- EV/EBITDA
- 34.0×
- Price/book
- 4.8×
- Gross margin
- 100.0%
- Operating margin
- 36.3%
- Net margin
- 57.8%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aimed Bio Inc. · KRX:0009K0 | US$722.1M | US$653.2M | 25.2× | 13.2× | 34.0× | 4.8× | 57.8% | 0.0× | n/a |
| MeiraGTx Holdings plc · NASDAQ:MGTX | US$766.4M | US$715.6M | 9.8× | 1.8× | 3.7× | 3.6× | 19.5% | 0.6× | 1.57 |
| ORIC Pharmaceuticals, Inc. · NASDAQ:ORIC | US$764.9M | US$503.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.22 |
| Inventiva SA · EURONEXT:IVA | US$760.9M | US$577.3M | n/a | 117× | n/a | 11.8× | n/a | 1.1× | n/a |
| Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL | US$754.9M | US$663.4M | 2.5× | 2.3× | 8.3× | 1.7× | 106.6% | 0.0× | 1.02 |
| Obsidian Therapeutics, Inc. · NASDAQ:OBX | US$741.3M | US$530.4M | 13.0× | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE | US$738.3M | US$196.8M | n/a | 2.8× | n/a | 1.5× | −186.2% | 0.1× | 0.92 |
| Aura Biosciences, Inc. · NASDAQ:AURA | US$715.0M | US$433.9M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.07 |
| Solid Biosciences Inc. · NASDAQ:SLDB | US$697.6M | US$368.3M | n/a | n/a | n/a | 2.0× | n/a | 0.1× | 1.85 |
| Attovia Therapeutics, Inc. · NASDAQ:ATTO | US$689.3M | US$297.2M | n/a | 220× | n/a | 1.7× | n/a | 0.0× | n/a |
| Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX | US$681.2M | US$549.9M | n/a | 14.3× | n/a | 4.2× | −161.8% | 0.3× | 1.15 |
| Median of the others | US$739.8M | US$517.0M | 9.8× | 8.5× | 6.0× | 2.3× | −71.2% | 0.1× | 1.15 |
Forecasts
Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- EPS, year to Dec 2026
- 170.00 · 1 analyst
- Revenue, year to Dec 2026
- 27.6B · 1 analyst
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 47.3B | 11.8B |
| Gross profit | 47.3B | 11.8B |
| Selling, general and administrative | 19.5B | 7.53B |
| Operating income | 20.8B | -407.8M |
| Depreciation and amortization | 1.38B | 1.46B |
| EBITDA | 22.2B | 1.06B |
| Interest expense | 57.0M | 93.1M |
| Income before tax | -4.16B | -3.31B |
| Net income | 5.02B | -3.30B |
| Earnings per share, basic | 78.29 | -51.50 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 106.4B | 4.49B |
| Short-term investments | 64.4B | 31.0B |
| Receivables | 3.30B | |
| Current assets | 178.5B | 36.2B |
| Total assets | 199.0B | 47.1B |
| Current liabilities | 5.68B | 43.6B |
| Total liabilities | 6.40B | 43.8B |
| Shareholders' equity | 192.6B | 3.36B |
| Shares outstanding | 64.2M | 64.2M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | 17.9B | -4.87B |
| Capital spending | -362.6M | -1.68B |
| Free cash flow | 17.5B | -6.55B |
| Change in cash | 101.9B | 3.03B |
Cap table
Built by 6ix from Aimed Bio Inc.’s releases
- Common shares
- 64,156,161
- Fully diluted
- 64,156,161
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 64,156,161 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 64,156,161 |
Log in to ask 6ix AI your own questions about Aimed Bio Inc.